350 related articles for article (PubMed ID: 11700390)
1. The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies.
Giles FJ
Oncologist; 2001; 6 Suppl 5():32-9. PubMed ID: 11700390
[TBL] [Abstract][Full Text] [Related]
2. The emerging role of angiogenesis inhibitors in hematologic malignancies.
Giles FJ
Oncology (Williston Park); 2002 May; 16(5 Suppl 4):23-9. PubMed ID: 12102577
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications.
Ellis LM; Takahashi Y; Liu W; Shaheen RM
Oncologist; 2000; 5 Suppl 1():11-5. PubMed ID: 10804085
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies.
List AF
Oncologist; 2001; 6 Suppl 5():24-31. PubMed ID: 11700389
[TBL] [Abstract][Full Text] [Related]
5. The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma.
Arastéh K; Hannah A
Oncologist; 2000; 5 Suppl 1():28-31. PubMed ID: 10804088
[TBL] [Abstract][Full Text] [Related]
6. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
Ferrara N
Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.
Rosen LS
Cancer Control; 2002; 9(2 Suppl):36-44. PubMed ID: 11965229
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis and angiogenic mediators in haematological malignancies.
Mangi MH; Newland AC
Br J Haematol; 2000 Oct; 111(1):43-51. PubMed ID: 11091181
[No Abstract] [Full Text] [Related]
9. VEGF receptor signaling in tumor angiogenesis.
McMahon G
Oncologist; 2000; 5 Suppl 1():3-10. PubMed ID: 10804084
[TBL] [Abstract][Full Text] [Related]
10. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors.
Schlaeppi JM; Wood JM
Cancer Metastasis Rev; 1999; 18(4):473-81. PubMed ID: 10855790
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Podar K; Anderson KC
Curr Cancer Drug Targets; 2011 Nov; 11(9):1005-24. PubMed ID: 21933109
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
13. Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.
Vajkoczy P; Thurnher A; Hirth KP; Schilling L; Schmiedek P; Ullrich A; Menger MD
Oncologist; 2000; 5 Suppl 1():16-9. PubMed ID: 10804086
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis inhibition in solid tumors.
Rosen LS
Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082
[TBL] [Abstract][Full Text] [Related]
15. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications.
Podar K; Anderson KC
Blood; 2005 Feb; 105(4):1383-95. PubMed ID: 15471951
[TBL] [Abstract][Full Text] [Related]
16. A targeted approach for antiangiogenic therapy of metastatic human colon cancer.
Ellis LM
Am Surg; 2003 Jan; 69(1):3-10. PubMed ID: 12575772
[TBL] [Abstract][Full Text] [Related]
17. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
[TBL] [Abstract][Full Text] [Related]
18. Role of angiogenesis inhibitors in acute myeloid leukemia.
Fiedler W; Staib P; Kuse R; Dührsen U; Flasshove M; Cavalli F; Hossfeld DK; Berdel WE
Cancer J; 2001; 7 Suppl 3():S129-33. PubMed ID: 11779083
[TBL] [Abstract][Full Text] [Related]
19. von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy.
Harris AL
Oncologist; 2000; 5 Suppl 1():32-6. PubMed ID: 10804089
[TBL] [Abstract][Full Text] [Related]
20. Angiogenic and lymphangiogenic molecules in hematological malignancies.
Orpana A; Salven P
Leuk Lymphoma; 2002 Feb; 43(2):219-24. PubMed ID: 11999550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]